A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Detalles Bibliográficos
Autores principales: Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116334/
https://www.ncbi.nlm.nih.gov/pubmed/33980831
http://dx.doi.org/10.1038/s41408-021-00478-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116334/
https://www.ncbi.nlm.nih.gov/pubmed/33980831
http://dx.doi.org/10.1038/s41408-021-00478-4

Ejemplares similares